Contacts

Tremendous success for MedinCell’s €30 million capital increase for qualified investors

February 11, 2021

Offer widely oversubscribed: 2.5 times the total amount of the capital increase
Strong support from French and international leading shareholders and investors


MedinCell (FR0004065605 – MEDCL), a clinical stage pharmaceutical company developing a portfolio of long-acting injectable products in various therapeutic areas (the “Company”), is today announcing the successful completion of its €29.8 million capital increase via a placement with French and international qualified investors through an accelerated bookbuilding process (the “Offering”).

Bryan, Garnier & Co. Limited1 and ODDO BHF SCA are acting as Joint Global Coordinators and Joint Bookrunners.

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.